Transderm Scop
NDC Package 10019-553-06

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Transderm Scop is transderm Scōp® is contraindicated in the following populations:•Patients with angle closure glaucoma. Marketed by Baxter Healthcare Corporation, this product is identified by NDC 10019-553 and is authorized under FDA application NDA017874.

Identification & Billing

NDC Package Code
10019-553-06
Package Description
4 POUCH in 1 BOX / 1 PATCH in 1 POUCH / 3 d in 1 PATCH
Product Code
10019-553
11-Digit Billing Format
10019055306
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Transderm Scop
Dosage Form
-
Usage Information
Transderm Scōp® is contraindicated in the following populations:•Patients with angle closure glaucoma. [see Adverse Reactions (6)]•Persons who are hypersensitive to the drug scopolamine or other belladonna alkaloids or to any ingredient or component in the formulation or delivery system. [see Drug Interactions (7) and Description (11)]

Regulatory & Marketing

Labeler Name
Baxter Healthcare Corporation
FDA Application #
NDA017874
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
01-01-2003
End Marketing Date
05-31-2019
Listing Expiration
05-31-2019
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (10019-553). Click a package code to view its specific billing and regulatory data.

10019-553-01
10 POUCH in 1 BOX / 1 PATCH in 1 POUCH / 3 d in 1 PATCH
10019-553-02
24 POUCH in 1 BOX / 1 PATCH in 1 POUCH / 3 d in 1 PATCH
10019-553-03
10 POUCH in 1 BOX / 1 PATCH in 1 POUCH / 3 d in 1 PATCH
10019-553-04
24 POUCH in 1 BOX / 1 PATCH in 1 POUCH / 3 d in 1 PATCH
10019-553-88
1 PATCH in 1 POUCH / 3 d in 1 PATCH
10019-553-90
1 PATCH in 1 POUCH / 3 d in 1 PATCH

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 10019-553-06 identifies a specific commercial package of 4 pouch in 1 box / 1 patch in 1 pouch / 3 d in 1 patch of Transderm Scop, labeled by Baxter Healthcare Corporation. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Baxter Healthcare Corporation on January 01, 2003. The current certification is valid through May 31, 2019.

How is this Baxter Healthcare Corporation product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 10019055306. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
10019-553-06
11-Digit CMS (5-4-2)
10019-0553-06

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.